CIK cell therapy for B-cell leukemia after CAR-T failure
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests CIK immune cells for children and young adults with B-cell acute lymphoblastic leukemia that stopped responding to CAR-T cell therapy within 6 months. The goal is to see if CIK cells can help when CAR-T cells no longer work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell acute lymphoblastic leukemia that came back or did not respond to treatment.
- Your CAR-T cell therapy stopped working within the past 6 months, but you have not relapsed yet.
- You are between 1 and 39 years old.
- You are in generally good health (able to do daily activities) and expected to live at least 2 months.
- You do not have other active cancers, severe infections, or serious organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
This trial tests a new CAR-T cell treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. It aims to see if these immune cells can safely and effectively fight the cancer.
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.